Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 48

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

232

HTML

1683

Tables (1-4)

145

Sum=2060

Dec 28, 2007 (publication date) through Jul 29, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Dec 28, 2007; 13(48): 6553-6557
Published online Dec 28, 2007. doi: 10.3748/wjg.v13.i48.6553

Table 3 Responses and survival rates (n = 31)

Response after three cycles	No. of patients (%)
PR	2 (6.5)
SD	16 (51.5)
Progression	13 (42)
Median progression-free survival (95% CI)	4 (1.7-7) mo
Overall survival rate
6 mo	21 (68)
12 mo	9 (29)
24 mo	1 (0.3)
Survival rate in
PR or SD patients (n = 18)
6 mo	15 (83)
12 mo	9 (50)
24 mo	1 (0.56)

Citation: Lorenzo GD, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, Stefano AD, Esposito V, Placido SD, Montesarchio V. Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study. World J Gastroenterol 2007; 13(48): 6553-6557
URL: https://www.wjgnet.com/1007-9327/full/v13/i48/6553.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i48.6553